Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| EchoNous Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ultrasound Guided Treatment | Experimental | Patients allocated to this will be guided (diuretic treatment) by ultrasound (VExUS) findings |
|
| Clinical Guided Treatment | Active Comparator | Patients allocated to this will be guided (diuretic treatment) by clinical congestion score (CCS) findings |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diuretic de/escalation based on ultrasound findings (VExUS Score) | Other | Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score) |
| Measure | Description | Time Frame |
|---|---|---|
| Decongestion within 7 days | Assess if the ultrasound guided arm achieves faster decongestion | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Acutely decompensated heart failure readmission rate | Assess which strategy achieves less readmission rate | 7 days |
| Length of hospital stay | Assess which strategy achieves fewer days of hospital stay |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Salvador López Gil, MD | Contact | 5555732911 | 24400 | salvadorlgil@gmail.com |
| Victor H Gomez Johnson, MD | Contact | 5591985387 | vgomezjohnson@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto Nacional de Cardiología Ignacio Chávez | Recruiting | Mexico City | 14080 | Mexico |
Will share the clinical study report and results when they´re available
2 months before finishing the study
Via email to principal investigator
Not provided
Not provided
Experimental, randomized, double-blind, and prospective study
Not provided
Not provided
Not provided
| Diuretic de/escalation based on clinical findings (CCS Score) | Other | Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score) |
|
| 7 days |
| Total diuretic dose within 7 days | Assess which strategy has greater diuretic adjustment | 7 days |
| Number of participants that initiate kidney replacement therapy | Assess which strategy is associated with kidney replacement therapy | 30 days |
| Intrahospital mortality | Assess which strategy achieves less intrahospital mortality | 30 days |
| Days alive out of hospital | Assess which strategy achieves more days alive out of hospital | 1 month |